News Releases | Subscribe

September 16, 2019

Myriad Announces Research Collaboration with University of Leeds

Clinical Utility Study will Evaluate the Prolaris® Test in Men with Prostate Cancer SALT LAKE CITY, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced it will collaborate with the Leeds Centre for

Read More

September 5, 2019

Prolaris® Test Identifies Men with Prostate Cancer Who Can Safely Defer Treatment

65 Percent of Patients Remained on Active Surveillance for More than Four Years SALT LAKE CITY, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced publication of results

Read More

August 30, 2019

Myriad Genetics to Present at the 2019 Morgan Stanley Global Healthcare Conference

SALT LAKE CITY, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled to present at the Morgan Stanley Global Healthcare Conference at 8:35 a.m.

Read More

August 13, 2019

Myriad Genetics Reports Fiscal Fourth-Quarter and Full-Year 2019 Financial Results

Total Fourth-Quarter Revenues of $215.4 Million Fourth-Quarter Diluted EPS of ($0.06) and Adjusted EPS of $0.41 SALT LAKE CITY, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today

Read More

August 6, 2019

Myriad to Announce Fiscal Fourth-Quarter 2019 Financial Results on August 13, 2019

SALT LAKE CITY, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it will hold its fiscal fourth-quarter 2019 sales and earnings conference call with investors and analysts at 4:30 p.m.

Read More

May 7, 2019

Myriad Genetics Reports Fiscal Third-Quarter 2019 Financial Results

Total Third-Quarter Revenues of $216.6 Million, Up 18 Percent Third-Quarter Diluted EPS of $0.09 and Adjusted EPS of $0.46, Up 35 Percent SALT LAKE CITY, May 07, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in personalized medicine, today

Read More

August 30, 2019

Myriad Genetics to Present at the 2019 Morgan Stanley Global Healthcare Conference

SALT LAKE CITY, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled to present at the Morgan Stanley Global Healthcare Conference at 8:35 a.m.

Read More

August 6, 2019

Myriad to Announce Fiscal Fourth-Quarter 2019 Financial Results on August 13, 2019

SALT LAKE CITY, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it will hold its fiscal fourth-quarter 2019 sales and earnings conference call with investors and analysts at 4:30 p.m.

Read More

June 5, 2019

Myriad Genetics to Present at the 2019 Goldman Sachs Global Healthcare Conference

SALT LAKE CITY, June 05, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled to present at the Goldman Sachs Global Healthcare Conference at 11:40 a.m.

Read More

September 16, 2019

Myriad Announces Research Collaboration with University of Leeds

Clinical Utility Study will Evaluate the Prolaris® Test in Men with Prostate Cancer SALT LAKE CITY, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced it will collaborate with the Leeds Centre for

Read More

September 5, 2019

Prolaris® Test Identifies Men with Prostate Cancer Who Can Safely Defer Treatment

65 Percent of Patients Remained on Active Surveillance for More than Four Years SALT LAKE CITY, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced publication of results

Read More

August 22, 2019

Myriad Applauds the U.S. Preventive Services Task Force Recommendation on BRCA-Related Cancer Prevention

More Women May Benefit from Hereditary Cancer Risk Assessment and Genetic Testing SALT LAKE CITY, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, today announced its support of the U.S.

Read More

September 16, 2019

Myriad Announces Research Collaboration with University of Leeds

Clinical Utility Study will Evaluate the Prolaris® Test in Men with Prostate Cancer SALT LAKE CITY, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced it will collaborate with the Leeds Centre for

Read More

September 5, 2019

Prolaris® Test Identifies Men with Prostate Cancer Who Can Safely Defer Treatment

65 Percent of Patients Remained on Active Surveillance for More than Four Years SALT LAKE CITY, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced publication of results

Read More

August 22, 2019

Myriad Applauds the U.S. Preventive Services Task Force Recommendation on BRCA-Related Cancer Prevention

More Women May Benefit from Hereditary Cancer Risk Assessment and Genetic Testing SALT LAKE CITY, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, today announced its support of the U.S.

Read More

Myriad Corporate Presentation
Fact Sheet
Company Milestones